BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37490033)

  • 1. Visible light-activatable platinum(IV) prodrugs harnessing CD36 for ovarian cancer therapy.
    Jayawardhana AMDS; Bhandari S; Kaspi-Kaneti AW; Kshetri M; Qiu Z; Cheline M; Shen H; Dunietz BD; Zheng YR
    Dalton Trans; 2023 Aug; 52(31):10942-10950. PubMed ID: 37490033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fatty acid-like Pt(IV) prodrugs overcome cisplatin resistance in ovarian cancer by harnessing CD36.
    Jayawardhana AMDS; Stilgenbauer M; Datta P; Qiu Z; Mckenzie S; Wang H; Bowers D; Kurokawa M; Zheng YR
    Chem Commun (Camb); 2020 Sep; 56(73):10706-10709. PubMed ID: 32789350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diazido mixed-amine platinum(IV) anticancer complexes activatable by visible-light form novel DNA adducts.
    Zhao Y; Woods JA; Farrer NJ; Robinson KS; Pracharova J; Kasparkova J; Novakova O; Li H; Salassa L; Pizarro AM; Clarkson GJ; Song L; Brabec V; Sadler PJ
    Chemistry; 2013 Jul; 19(29):9578-91. PubMed ID: 23733242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mono- and di-bromo platinum(IV) prodrugs via oxidative bromination: synthesis, characterization, and cytotoxicity.
    Xu Z; Wang Z; Yiu SM; Zhu G
    Dalton Trans; 2015 Dec; 44(46):19918-26. PubMed ID: 26514681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Photoactivatable Cell-Selective Dinuclear trans-Diazidoplatinum(IV) Anticancer Prodrugs.
    Shi H; Romero-Canelón I; Hreusova M; Novakova O; Venkatesh V; Habtemariam A; Clarkson GJ; Song JI; Brabec V; Sadler PJ
    Inorg Chem; 2018 Nov; 57(22):14409-14420. PubMed ID: 30365308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent Chlorambucil-Platinum(IV) Prodrugs.
    Aputen AD; Elias MG; Gilbert J; Sakoff JA; Gordon CP; Scott KF; Aldrich-Wright JR
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functionalized nonporous silica nanoparticles as carriers for Pt(iv) anticancer prodrugs.
    Ravera M; Gabano E; Zanellato I; Perin E; Arrais A; Osella D
    Dalton Trans; 2016 Nov; 45(43):17233-17240. PubMed ID: 27722707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards rational design of RAD51-targeting prodrugs: platinum
    Zhang S; Yuan H; Guo Y; Wang K; Wang X; Guo Z
    Chem Commun (Camb); 2018 Oct; 54(83):11717-11720. PubMed ID: 30229259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Photoinduced reduction of Pt(IV) within an anti-proliferative Pt(IV)-texaphyrin conjugate.
    Thiabaud G; Arambula JF; Siddik ZH; Sessler JL
    Chemistry; 2014 Jul; 20(29):8942-7. PubMed ID: 24961491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional fluorescent nonporous silica nanoparticles as carriers for Pt(IV) anticancer prodrugs.
    Ravera M; Perin E; Gabano E; Zanellato I; Panzarasa G; Sparnacci K; Laus M; Osella D
    J Inorg Biochem; 2015 Oct; 151():132-42. PubMed ID: 26277416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted iron nanoparticles with platinum-(IV) prodrugs and anti-EZH2 siRNA show great synergy in combating drug resistance in vitro and in vivo.
    Yu C; Ding B; Zhang X; Deng X; Deng K; Cheng Z; Xing B; Jin D; Ma P; Lin J
    Biomaterials; 2018 Feb; 155():112-123. PubMed ID: 29175080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering liposomal nanoparticles of cholesterol-tethered amphiphilic Pt(iv) prodrugs with prolonged circulation time in blood.
    Datta P; Bang S; Yue Z; Beach T; Stilgenbauer M; Wang H; Bowers DJ; Kurokawa M; Xiao H; Zheng YR
    Dalton Trans; 2020 Jun; 49(24):8107-8113. PubMed ID: 32490446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BODI-Pt, a Green-Light-Activatable and Carboplatin-Based Platinum(IV) Anticancer Prodrug with Enhanced Activation and Cytotoxicity.
    Yao H; Chen S; Deng Z; Tse MK; Matsuda Y; Zhu G
    Inorg Chem; 2020 Aug; 59(16):11823-11833. PubMed ID: 32799491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An integrin-targeted photoactivatable Pt(IV) complex as a selective anticancer pro-drug: synthesis and photoactivation studies.
    Gandioso A; Shaili E; Massaguer A; Artigas G; González-Cantó A; Woods JA; Sadler PJ; Marchán V
    Chem Commun (Camb); 2015 Jun; 51(44):9169-72. PubMed ID: 25947177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spin-labelled photo-cytotoxic diazido platinum(iv) anticancer complex.
    Venkatesh V; Wedge CJ; Romero-Canelón I; Habtemariam A; Sadler PJ
    Dalton Trans; 2016 Aug; 45(33):13034-7. PubMed ID: 27189101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An upconversion nanoplatform for simultaneous photodynamic therapy and Pt chemotherapy to combat cisplatin resistance.
    Ai F; Sun T; Xu Z; Wang Z; Kong W; To MW; Wang F; Zhu G
    Dalton Trans; 2016 Aug; 45(33):13052-60. PubMed ID: 27430044
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Lee VEY; Lim ZC; Chew SL; Ang WH
    Inorg Chem; 2021 Feb; 60(3):1823-1831. PubMed ID: 33464875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
    Ma ZY; Wang DB; Song XQ; Wu YG; Chen Q; Zhao CL; Li JY; Cheng SH; Xu JY
    Eur J Med Chem; 2018 Sep; 157():1292-1299. PubMed ID: 30195239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-Acting Mitochondria-Targeted Platinum(IV) Prodrugs of Kiteplatin with α-Lipoic Acid in the Axial Positions.
    Savino S; Marzano C; Gandin V; Hoeschele JD; Natile G; Margiotta N
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Pt(IV) Prodrug Combining Chlorambucil and Cisplatin: a Dual-Acting Weapon for Targeting DNA in Cancer Cells.
    Montagner D; Tolan D; Andriollo E; Gandin V; Marzano C
    Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30486477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.